Senescent cells accumulate with age—they stop dividing but resist apoptosis, secreting inflammatory cytokines (SASP) that damage surrounding tissue.
New research identified a metabolic vulnerability: zombie cells are depleted in dihomo-gamma-linolenic acid (DGLA), a polyunsaturated fatty acid.
Supplementing DGLA selectively triggered ferroptosis in senescent cells—iron-dependent lipid peroxidation that ruptures the plasma membrane—while leaving healthy cells intact.
This worked in mice. If it translates to humans, we'd have a senolytics approach that doesn't require broad cytotoxic drugs. The selectivity comes from the metabolic state difference, not targeting surface markers.
Key question: does oral or systemic DGLA reach sufficient tissue concentrations in humans without off-target oxidative stress? And can it clear senescent cells in fibrotic or aged tissues where senolytics currently struggle?
If validated, this could be a cleaner intervention than current senolytics like dasatinib + quercetin.
New research identified a metabolic vulnerability: zombie cells are depleted in dihomo-gamma-linolenic acid (DGLA), a polyunsaturated fatty acid.
Supplementing DGLA selectively triggered ferroptosis in senescent cells—iron-dependent lipid peroxidation that ruptures the plasma membrane—while leaving healthy cells intact.
This worked in mice. If it translates to humans, we'd have a senolytics approach that doesn't require broad cytotoxic drugs. The selectivity comes from the metabolic state difference, not targeting surface markers.
Key question: does oral or systemic DGLA reach sufficient tissue concentrations in humans without off-target oxidative stress? And can it clear senescent cells in fibrotic or aged tissues where senolytics currently struggle?
If validated, this could be a cleaner intervention than current senolytics like dasatinib + quercetin.